A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma

We studied the function of antitumor T and natural killer T (NKT) cells from the blood and tumor bed in 23 patients with premalignant gammopathy, nonprogressive myeloma, or progressive multiple myeloma. We show that antitumor killer T cells can be detected in patients with both progressive or nonprogressive myeloma. Vα24+Vβ11+ invariant NKT cells are detectable in the blood and tumor bed of all cohorts. However, freshly isolated NKT cells from both the blood and tumor bed of patients with progressive disease, but not nonprogressive myeloma or premalignant gammopathy, have a marked deficiency of ligand-dependent interferon-γ production. This functional defect can be overcome in vitro using dendritic cells pulsed with the NKT ligand, α-galactosylceramide (α-GalCer). Fresh myeloma cells express CD1d, and can be efficiently killed by autologous NKT cells. We hypothesize that presentation of tumor derived glycolipids by myeloma cells leads to NKT dysfunction in vivo. These data demonstrate that clinical progression in patients with monoclonal gammopathies is associated with an acquired but potentially reversible defect in NKT cell function and support the possibility that these innate lymphocytes play a role in controlling the malignant growth of this incurable B cell tumor in patients.

[1]  R. Steinman,et al.  Detection and activation of human Vα24+ natural killer T cells using α-galactosyl ceramide-pulsed dendritic cells☆ , 2003 .

[2]  M. Dhodapkar,et al.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Kyle,et al.  Monoclonal gammopathies of undetermined significance. , 2002, Reviews in clinical and experimental hematology.

[4]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[5]  R. Steinman,et al.  Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs , 2002, Nature Immunology.

[6]  D. Nixon,et al.  Selective Loss of Innate CD4+ Vα24 Natural Killer T Cells in Human Immunodeficiency Virus Infection , 2002, Journal of Virology.

[7]  Michael J. Green,et al.  Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. , 2002, Blood.

[8]  M. Smyth,et al.  A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas , 2002, The Journal of experimental medicine.

[9]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[10]  M. Nozue,et al.  Impaired Proliferative Response of Vα24 NKT Cells from Cancer Patients Against α-Galactosylceramide1 , 2002, The Journal of Immunology.

[11]  J. Blum,et al.  Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Takashi Yamamura,et al.  Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining , 2002, The Journal of experimental medicine.

[13]  L. Teyton,et al.  Distinct Functional Lineages of Human Vα24 Natural Killer T Cells , 2002, The Journal of experimental medicine.

[14]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[15]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[16]  M. Dhodapkar,et al.  Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells , 2002, The Journal of experimental medicine.

[17]  R. Vile.  Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .

[18]  G. Bubley,et al.  Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer1 , 2001, The Journal of Immunology.

[19]  R. Seeger,et al.  Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells1 , 2001, The Journal of Immunology.

[20]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[21]  Y. Tanaka,et al.  TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. , 2001, Blood.

[22]  M. Smyth,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.

[23]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[24]  S. Ullrich,et al.  Immune suppression and skin cancer development: regulation by NKT cells , 2000, Nature Immunology.

[25]  A. Bendelac,et al.  CD1d-restricted mouse Vα14 and human Vα24 T cells: lymphocytes of innate immunity , 2000 .

[26]  M. Smyth,et al.  NKT cells: facts, functions and fallacies. , 2000, Immunology today.

[27]  A. Bendelac,et al.  CD1-restricted T-cell responses and microbial infection , 2000, Nature.

[28]  K. Tadokoro,et al.  Human invariant Vα24+ natural killer T cells activated by α‐galactosylceramide (KRN7000) have cytotoxic anti‐tumour activity through mechanisms distinct from T cells and natural killer cells , 2000, Immunology.

[29]  T. Iizasa,et al.  Antitumor Cytotoxicity Mediated by Ligand-activated Human Vα24 NKT Cells , 1999 .

[30]  M. Taniguchi,et al.  Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. , 1999, Journal of immunology.

[31]  R. Steinman,et al.  Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. , 1999, The Journal of clinical investigation.

[32]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[33]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[34]  Y. Tanaka,et al.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Nakagawa,et al.  Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. , 1998, Cancer research.

[36]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[37]  B. Klein,et al.  gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro , 1993 .

[38]  R. Steinman,et al.  Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells. , 2003, Journal of immunological methods.

[39]  M. Nozue,et al.  Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. , 2002, Journal of immunology.

[40]  René Bernards,et al.  A progression puzzle. , 2002, Nature.

[41]  G. Giaccone,et al.  Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. , 2001, Journal of immunological methods.

[42]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[43]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[44]  A. Bendelac,et al.  CD1d-restricted mouse V alpha 14 and human V alpha 24 T cells: lymphocytes of innate immunity. , 2000, Seminars in immunology.

[45]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[46]  T. Iizasa,et al.  Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. , 1999, Cancer research.

[47]  K. Tadokoro,et al.  Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. , 1999, Human immunology.

[48]  K. Tadokoro,et al.  Activation of human Vα24NKT cells by α-glycosylceramide in a CD1d-restricted and Vα24TCR-mediated manner , 1999 .

[49]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  C. E. Mengel,et al.  Hematology : principles and practice , 1972 .